clinical trial · NCT07156136
Study of IMC-P115C in Advanced PRAME-Positive Cancers
PRAME PositiveCancerHLA-A*02:01-positiveIMC-P115C
brief summary
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
started
Nov 7, 2024
primary completion
Sep 30, 2027
completion
Aug 30, 2029
last updated
Feb 25, 2026
official title
A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol